ImmunityBio (IBRX) Depreciation & Amortization (CF) (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Depreciation & Amortization (CF) data on file, last reported at $4.4 million in Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $4.4 million, up 14.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $16.1 million (down 4.47% YoY), and the FY2025 annual result was $15.5 million, down 11.56% from the prior year.
• Depreciation & Amortization (CF) advanced to $4.4 million in Q1 2026 per IBRX's latest filing, from $3.9 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $5.2 million in Q4 2022 and troughed at $3.8 million in Q1 2025.
• A 5-year average of $4.4 million and a median of $4.4 million in 2022 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2022 and 2025: Depreciation & Amortization (CF) surged 45.37% in 2022, then retreated 15.94% in 2025.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $5.2 million in 2022, then slipped by 12.67% to $4.6 million in 2023, then slipped by 9.33% to $4.1 million in 2024, then fell by 6.6% to $3.9 million in 2025, then advanced by 13.32% to $4.4 million in 2026.
• Business Quant data shows IBRX's Depreciation & Amortization (CF) at $4.4 million in Q1 2026, $3.9 million in Q4 2025, and $4.0 million in Q3 2025.